DLX1 and cancer: Recent advancements with the development of small molecular inhibitors, peptidomimetics62, and proteolysis-targeting chimera (PROTAC)63 show promise in targeting transcription factors in cancers, thus paving a way to exploit DLX1 as a potential drug target.